Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The brokerage presently has a $17.00 price target on the medical research company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 20.14% from the stock’s current price.

According to Zacks, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. “

Other analysts also recently issued research reports about the company. BidaskClub upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. JPMorgan Chase & Co. downgraded Accelerate Diagnostics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $25.00 to $16.00 in a research note on Wednesday, November 7th. Finally, ValuEngine downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 27th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $20.50.

Shares of AXDX traded down $0.76 during mid-day trading on Friday, reaching $14.15. The company had a trading volume of 390,449 shares, compared to its average volume of 261,116. Accelerate Diagnostics has a 52-week low of $12.70 and a 52-week high of $30.35. The company has a quick ratio of 33.54, a current ratio of 35.26 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $776.67 million, a price-to-earnings ratio of -12.20 and a beta of 2.48.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its earnings results on Tuesday, November 6th. The medical research company reported ($0.41) EPS for the quarter, hitting analysts’ consensus estimates of ($0.41). Accelerate Diagnostics had a negative return on equity of 81.76% and a negative net margin of 1,365.75%. The firm had revenue of $1.36 million for the quarter, compared to the consensus estimate of $2.89 million. As a group, equities analysts anticipate that Accelerate Diagnostics will post -1.61 EPS for the current fiscal year.

In other news, Director Thomas D. Brown bought 10,000 shares of Accelerate Diagnostics stock in a transaction on Wednesday, November 28th. The stock was acquired at an average price of $13.65 per share, with a total value of $136,500.00. Following the completion of the acquisition, the director now directly owns 16,381 shares of the company’s stock, valued at $223,600.65. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired 21,600 shares of company stock valued at $308,301 in the last three months. Insiders own 49.30% of the company’s stock.

Several institutional investors have recently made changes to their positions in AXDX. FMR LLC increased its holdings in shares of Accelerate Diagnostics by 97.8% in the second quarter. FMR LLC now owns 486,500 shares of the medical research company’s stock valued at $10,849,000 after purchasing an additional 240,600 shares during the last quarter. Baird Financial Group Inc. increased its holdings in shares of Accelerate Diagnostics by 3.7% in the second quarter. Baird Financial Group Inc. now owns 154,359 shares of the medical research company’s stock valued at $3,442,000 after purchasing an additional 5,477 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Accelerate Diagnostics by 4.2% in the second quarter. BlackRock Inc. now owns 1,750,891 shares of the medical research company’s stock valued at $39,046,000 after purchasing an additional 70,447 shares during the last quarter. Trellus Management Company LLC acquired a new stake in shares of Accelerate Diagnostics in the third quarter valued at approximately $566,000. Finally, Chicago Capital LLC increased its holdings in shares of Accelerate Diagnostics by 17.1% in the third quarter. Chicago Capital LLC now owns 630,053 shares of the medical research company’s stock valued at $14,460,000 after purchasing an additional 91,862 shares during the last quarter. 48.52% of the stock is owned by institutional investors and hedge funds.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Featured Article: What are municipal bonds?

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.